PLK2 and acute myeloid leukemia: This accounts for glioblastoma [168], hepatocellular carcinoma [169], acute myeloid leukemia [170], and for B-cell malignancies [171] where PLK2 is epigenetically silenced, as well as for cervical cancer where PLK2 exhibits anti-proliferative and apoptosis-promoting effects [172].